Investigating the Association Between Semaglutide Use and Mood Disorders in Polyendocrine Metabolic Ovarian Syndrome: A Retrospective Cohort Study
Abstract
Objective: This retrospective cohort study aims to evaluate whether semaglutide use in patients with polyendocrine metabolic ovarian syndrome (PMOS) is associated with an increased risk of mood disorders compared to patients treated with metformin by utilizing a large, propensity-matched dataset from TriNetX.
Methodology: The TriNetX platform was used to conduct a retrospective cohort study with International Classification of Diseases, 10th Revision (ICD-10) codes to generate inclusion and exclusion criteria. After propensity matching, each cohort consisted of 20,535 patients, for a total sample size of 41,070. Cohort 1 (patients with PMOS and on metformin) and Cohort 2 (patients with PMOS and on semaglutide) were evaluated for outcomes of new-onset major depressive disorder, generalized anxiety disorder, insomnia, and suicidal ideation that emerged after the start of the medication of interest.
Results: There was no statistically significant difference in generalized anxiety disorder and suicidal ideation associated with semaglutide use as compared to metformin in women with PMOS. However, there was a minor statistically significant difference in the rates of insomnia and major depressive disorder.
Conclusions: These results suggest that psychiatric considerations alone should not preclude the use of semaglutide in PMOS management. Ongoing mental health screening and follow-up remain essential for all patients with PMOS, regardless of treatment choice.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20,535 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.